combination, they had 1.26-fold natamycin MICs (95% CI, 0.70-to 2.28-fold; P = .44) and 2.57-fold voriconazole MICs (95% CI, 0.46-to 14.32-fold; P = .27) compared with no pretreatment. Table 2 shows median and 90th percentile MIC data for Fusarium, Aspergillus, and all other organisms by pretreatment status.
gal medications may similarly select for resistant fungi. Resistance among invasive fungal species has now been recognized as an important clinical concern.
2, 3 The Mycotic Ulcer
Treatment Trial I (MUTT I) was a randomized, controlled, double-masked trial that found topical natamycin to be superior to voriconazole in the treatment of filamentous fungal ulcers. 4 Herein, we evaluate the effect of pretreatment with antifungal medications on natamycin and voriconazole minimum inhibitory concentration (MIC) from baseline cultures collected during MUTT I.
Methods | Detailed methods for the clinical trial and for handling of microbiological specimens have been published previously. 4, 5 In brief, corneal scrapings and cultures were obtained from all patients at enrollment. Patients were eligible for inclusion if fungus was found on potassium hydroxide wet mount preparation and Gram staining was negative for bacteria. All culture-positive specimens underwent susceptibility testing using the standards set by the Clinical and Laboratory Standards Institute. 6 A t test was used to analyze the association between pretreatment with antifungal medications and baseline log 2 -transformed natamycin and voriconazole MICs for Aspergillus, Fusarium, and all other ulcers. Ethical approval for the study was obtained from the Aravind Eye Care System Institutional Review Board, the University of California, San Francisco Committee on Human Research, and the Dartmouth-Hitchcock Medical Center Committee for the Protection of Human Subjects. Written informed consent was obtained from all participants, and the trial conformed to the Declaration of Helsinki.
Results | Baseline culture and MIC data were available for 221 of 323 study participants (68%) and were included in the analysis. Eighty-eight participants (40%) were female and the median age was 46 years (interquartile range, 38-55 years). A difference was not identified in the pretreated vs nonpretreated groups regarding age or sex. Table 1 outlines pretreatment drugs and duration as well as fold change in MICs between groups. Among the 90 patients who were pretreated, 42 (47%) were pretreated with natamycin alone, 14 (16%) with an azole, and 34 (38%) with both an azole and natamycin. The mean duration of pretreatment was 5.7 days for natamycin and 3.8 days for azole alone. The azole was topical in 45 participants (94%), oral in 6 (12%), and both in 3 (6%).
Of the 126 Fusarium ulcers, 58 (46%) were pretreated. Fusarium isolates showed 0.89-fold (lower) natamycin MICs (95% CI, 0.70-to 1.11-fold; P = .30) when pretreated with natamycin alone and 1.12-fold voriconazole MICs (95% CI, 0.62-to 2.03-fold; P = .70) when pretreated with an azole alone compared with no pretreatment. When pretreated in combination, they had 0.75-fold natamycin MICs (95% CI, 0.51-to 1.09-fold; P = .12) and 0.90-fold voriconazole MICs (95% CI, 0.63-to 1.28-fold; P = .55) compared with no pretreatment.
Of the 52 Aspergillus ulcers, 22 (42%) were pretreated. Aspergillus isolates showed 1.64-fold (higher) natamycin MICs (95% CI, 0.77-to 3.48-fold; P = .19) when pretreated with natamycin alone and demonstrated 1.16-fold voriconazole MICs (95% CI, 0.48-to 2.81-fold; P = .73) when pretreated with an azole alone compared with no pretreatment. When treated in combination, they had 1.91-fold natamycin MICs (95% CI, 0.57-to 6.36-fold; P = .28) and 0.82-fold voriconazole MICs (95% CI, 0.33-to 2.03-fold; P = .66) compared with no pretreatment.
Among the 43 remaining ulcers, 10 (23%) were pretreated. Non-Fusarium, non-Aspergillus isolates showed 0.57-fold natamycin MICs (95% CI, 0.35-to 0.93-fold; P = .03) when treated with natamycin alone and 1.02-fold voriconazole MICs (95% CI, 0.50-to 4.14-fold; P = .98) when treated with an azole alone compared with no pretreatment. When pretreated in 
